SCHEMBL12850737

SCHEMBL12850737

ClOCc1cnc2ccc(Br)cc2c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.38
BACE1 P56817 1/20 0.36
PABPC1 P11940 1/20 0.35
PDE10A Q9Y233 5/20 0.34
BIRC5 O15392 1/20 0.34
MAOB P27338 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 2/20 0.33
APP P05067 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
NOS1 P29475 1/20 0.33
METAP2 P50579 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CCR5 P51681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30718698 0.85 PDE10A (0.43) MALT1BACE1PDE10APDGFRBPDGFRA
SCHEMBL27140044 0.85 PDE10A (0.43) MALT1BACE1PDE10APDGFRBPDGFRA
SCHEMBL12928151 0.80 PDE10A (0.34) PDE10APDGFRBPDGFRA
SCHEMBL2621781 0.79 BACE1 (0.38) MALT1BACE1PDE10ABIRC5MEN1
SCHEMBL18562139 0.79 CYP1A2 (0.40) MALT1BACE1PDE10ABIRC5MEN1
SCHEMBL9638 0.77 TLR2 (0.37) MALT1BACE1BIRC5MEN1KMT2A
SCHEMBL20528292 0.76 BACE1 (0.47) MALT1BACE1PABPC1BIRC5MEN1
SCHEMBL12277481 0.75 HTT (0.41) PDE10ABIRC5MEN1KMT2AHTT
SCHEMBL2621783 0.75 HTT (0.39) MALT1BACE1PDGFRBPDGFRAHTT
SCHEMBL22798927 0.74 NFKB1 (0.51) PDE10APDGFRBPDGFRAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 US disclosed
WO-2012148540-A1 COMBINATION OF KANASE INHIBITORS AND USES THREOF INTELLIKINE, LLC (US) 2012-11-01 WO disclosed
WO-2012116237-A2 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, LLC (US) 2012-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF MTOR, AKT2, MTMR1 MALT1 715/4885BACE1 1049/4885PABPC1 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.